Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

[-2]proPSA for predicting biochemical recurrence of prostate cancer earlier than total PSA after radical prostatectomy: an observational prospective cohort study.

Casale P, Saita A, Lazzeri M, Lughezzani G, Hurle R, Fasulo V, Mondellini GM, Paciotti M, Domanico L, Lista G, Maffei D, Monari M, Motta L, Bini V, Ceriotti F, Guazzoni G, Buffi N.

Minerva Urol Nefrol. 2019 Jan 28. doi: 10.23736/S0393-2249.19.03279-X. [Epub ahead of print]

PMID:
30700081
2.

Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.

Guazzoni G, Lazzeri M, Nava L, Lughezzani G, Larcher A, Scattoni V, Gadda GM, Bini V, Cestari A, Buffi NM, Freschi M, Rigatti P, Montorsi F.

Eur Urol. 2012 Mar;61(3):455-66. doi: 10.1016/j.eururo.2011.10.038. Epub 2011 Nov 4.

PMID:
22078333
3.

Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.

Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, Scattoni V, Bini V, Freschi M, Sussman A, Ghaleh B, Le Corvoisier P, Alberola Bou J, Esquena Fernández S, Graefen M, Guazzoni G.

Eur Urol. 2013 Jun;63(6):986-94. doi: 10.1016/j.eururo.2013.01.011. Epub 2013 Jan 24.

PMID:
23375961
4.

Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study.

Fossati N, Buffi NM, Haese A, Stephan C, Larcher A, McNicholas T, de la Taille A, Freschi M, Lughezzani G, Abrate A, Bini V, Palou Redorta J, Graefen M, Guazzoni G, Lazzeri M.

Eur Urol. 2015 Jul;68(1):132-8. doi: 10.1016/j.eururo.2014.07.034. Epub 2014 Aug 16.

PMID:
25139197
5.

Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy.

Eminaga O, Bögemann M, Breil B, Titze U, Wötzel F, Eltze E, Bettendorf O, Semjonow A.

Urol Oncol. 2014 Nov;32(8):1317-26. doi: 10.1016/j.urolonc.2014.04.018. Epub 2014 Jun 2.

PMID:
24893699
6.

Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.

Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, Dorigatti F, Ceriotti F, Pontillo M, Bini V, Freschi M, Montorsi F, Rigatti P.

Eur Urol. 2011 Aug;60(2):214-22. doi: 10.1016/j.eururo.2011.03.052. Epub 2011 Apr 5.

PMID:
21482022
7.

Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population.

Na R, Ye D, Liu F, Chen H, Qi J, Wu Y, Zhang G, Wang M, Wang W, Sun J, Yu G, Zhu Y, Ren S, Zheng SL, Jiang H, Sun Y, Ding Q, Xu J.

Prostate. 2014 Nov;74(15):1569-75. doi: 10.1002/pros.22876. Epub 2014 Aug 31.

PMID:
25176131
8.

Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.

Mearini L, Ferri C, Lazzeri M, Bini V, Nunzi E, Fiorini D, Costantini E, Manasse GC, Porena M.

Urol Int. 2014;93(2):135-45. doi: 10.1159/000356240. Epub 2014 Apr 8.

PMID:
24732975
9.

Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.

Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta JP, McNicholas T, Lughezzani G, Lista G, Larcher A, Bini V, Cestari A, Buffi N, Graefen M, Bosset O, Le Corvoisier P, Breda A, de la Torre P, Fowler L, Roux J, Guazzoni G.

BJU Int. 2013 Aug;112(3):313-21. doi: 10.1111/bju.12217.

10.

Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer.

Huang YQ, Sun T, Zhong WD, Wu CL.

Am J Clin Exp Urol. 2014 Dec 25;2(4):343-50. eCollection 2014. Review.

11.

Influence of age on seven putative prostate tumor markers: a cohort study in Chinese men.

Sun WG, Liang CZ, Zheng QC, Hu XW, Li ZZ, Wu P.

Asian J Androl. 2017 Jul-Aug;19(4):463-467. doi: 10.4103/1008-682X.175787.

12.

Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study.

Fossati N, Lazzeri M, Haese A, McNicholas T, de la Taille A, Buffi NM, Lughezzani G, Gadda GM, Lista G, Larcher A, Abrate A, Mistretta F, Bini V, Redorta JP, Graefen M, Guazzoni G.

BJU Int. 2015 Jun;115(6):913-20. doi: 10.1111/bju.12718. Epub 2015 Mar 26.

13.

Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.

Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A.

Clin Chem. 2013 Jan;59(1):306-14. doi: 10.1373/clinchem.2012.195784. Epub 2012 Dec 4.

14.

Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination.

Lazzeri M, Abrate A, Lughezzani G, Gadda GM, Freschi M, Mistretta F, Lista G, Fossati N, Larcher A, Kinzikeeva E, Buffi N, Dell'Acqua V, Bini V, Montorsi F, Guazzoni G.

Urology. 2014 Mar;83(3):606-12. doi: 10.1016/j.urology.2013.10.016. Epub 2013 Dec 6.

PMID:
24315305
15.

A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases.

Stephan C, Kahrs AM, Cammann H, Lein M, Schrader M, Deger S, Miller K, Jung K.

Prostate. 2009 Feb 1;69(2):198-207. doi: 10.1002/pros.20872.

PMID:
18942119
16.

Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study.

Park H, Lee SW, Song G, Kang TW, Jung JH, Chung HC, Kim SJ, Park CH, Park JY, Shin TY, Suh IB, Kim JH.

J Korean Med Sci. 2018 Mar 12;33(11):e94. doi: 10.3346/jkms.2018.33.e94.

17.

Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature.

Abrate A, Lughezzani G, Gadda GM, Lista G, Kinzikeeva E, Fossati N, Larcher A, Dell'Oglio P, Mistretta F, Buffi N, Guazzoni G, Lazzeri M.

Korean J Urol. 2014 Jul;55(7):436-45. doi: 10.4111/kju.2014.55.7.436. Epub 2014 Jul 11. Review.

18.

Prostate Health Index and %p2PSA Predict Aggressive Prostate Cancer Pathology in Chinese Patients Undergoing Radical Prostatectomy.

Chiu PK, Lai FM, Teoh JY, Lee WM, Yee CH, Chan ES, Hou SM, Ng CF.

Ann Surg Oncol. 2016 Aug;23(8):2707-14. doi: 10.1245/s10434-016-5183-6. Epub 2016 Mar 10.

PMID:
26965697
19.

Use of the Prostate Health Index for the Detection of Aggressive Prostate Cancer at Radical Prostatectomy.

Mearini L, Nunzi E, Ferri C, Bellezza G, Lolli C, Porrozzi C, Porena M.

Urol Int. 2015;95(4):390-9. doi: 10.1159/000379758. Epub 2015 Mar 17.

PMID:
25792149
20.

[-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report.

De Luca S, Passera R, Sottile A, Fiori C, Scarpa RM, Porpiglia F.

BMC Urol. 2016 Mar 24;16:14. doi: 10.1186/s12894-016-0131-0.

Supplemental Content

Support Center